-
VIVA Biotech Expands Global Footprint with New Boston Branch
•
China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its branch in Boston, USA, marking a significant step in the company’s global expansion strategy. Enhancing International Collaboration NetworksThe establishment of the Boston branch is expected to significantly enhance VIVA Bio’s international collaboration networks. This move…
-
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
•
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases, has raised an additional USD 12.5 million in financing. The company is jointly incubated by China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873). Existing investors Engine Ventures and Safar Partners spearheaded the funding…
-
VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology
•
VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a licensing agreement with Swiss Contract Manufacturing Organization (CMO) Lonza, securing access to Lonza’s innovative bYlok bispecific pairing technology. Financial terms of the agreement were not disclosed. Lonza’s bYlok technology addresses the prevalent industry challenge of…
-
VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round
•
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of a financing round, securing close to USD 210 million with backing from Temasek, Highlight Capital (HLC), and True Light. The Viva Biotech Holdings group obtained nearly USD 150 million through the transfer of approximately 24.21%…
-
Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program
•
US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva Biotech (HKG: 1873), has announced an exclusive license agreement and research agreement with US pharmaceutical giant Pfizer (NYSE: PFE). Under the terms of the agreement, Pfizer will receive exclusive rights to a Riparian preclinical program…
-
Novartis Acquires DTx Pharma and Its FALCON Technology for Up to $1 Billion
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced the acquisition of DTx Pharma Inc., a preclinical stage biotech company jointly incubated by Viva Biotech Holdings (HKG: 1873). The transaction includes a USD 500 million upfront payment and potential additional payments of up to USD 500 million upon the achievement of…
-
VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities
•
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a stake in its Shanghai unit to entities backed by Singapore’s investment fund Temasek and China-based HighLight Capital, raising RMB 1.06 billion (USD 148.7 million). This transaction reduces VIVA Biotech’s stake in VIVA Shanghai from 100%…
